Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

Getting an Answer: Tests and Tools for Diagnosis

At a Glance

NIID is diagnosed by combining several kinds of evidence rather than relying on one test: a ribbon-like MRI signal, a NOTCH2NLC gene expansion, and protein inclusions found on skin biopsy. Doctors may also test for similar conditions.

Diagnosing Neuronal Intranuclear Inclusion Disease (NIID) was once extremely difficult because it overlaps with so many other conditions. Today, doctors use a “multimodal” approach—combining imaging, genetics, and pathology—to confirm a diagnosis [1][2].

Because no single test is 100% perfect, your medical team will look for a pattern of evidence across these different areas to provide you with an accurate answer.

The “DWI Ribbon” Sign on MRI

One of the most powerful clues for NIID is found on a brain MRI, specifically using a setting called DWI (Diffusion-Weighted Imaging).

In many people with NIID, a bright, “ribbon-like” signal appears at the corticomedullary junction—the border where the brain’s “gray matter” meets the “white matter” [3][4].

  • Sensitivity: This sign is present in about 88% of adults in some NIID cohorts, making it a very strong indicator [3].
  • Specificity: This sign is highly specific (over 98% in some studies), meaning if it is present, there is a very high chance the person has NIID [3].
  • Timing: This signal can change over time. It may be absent in the early stages, disappear in very late stages, or fluctuate during “stroke-like” episodes [4][5].

Genetic Testing for NOTCH2NLC

Testing for an expansion in the NOTCH2NLC gene is a cornerstone of the diagnosis [2].

  • The Repeat: Doctors look for a “GGC” sequence that repeats more than 60 times, though cutoffs vary by lab [6].
  • Methods: Standard genetic tests may use a technique called RP-PCR (Repeat-Primed Polymerase Chain Reaction) to count these repeats. In complex cases, specialized labs might use long-read sequencing, which can “read” through very large or messy expansions that standard tests might miss [2][7].
  • A “Negative” Result: If your genetic test is negative but your symptoms and MRI strongly suggest NIID, your doctor may still pursue a skin biopsy, as rare genetic variations can sometimes hide from standard tests, or another condition may be the true cause [6][8].

The Role of Skin Biopsy

Because the toxic protein clumps (inclusions) in NIID are found throughout the body, a small skin biopsy can often provide supportive diagnostic evidence [9].

  • What they look for: Pathologists look for round, glassy clumps inside the nucleus of cells in your sweat glands, fat cells, or fibroblasts [9][6].
  • Staining: To see these clumps clearly, the tissue is treated with special “stains” for proteins called p62 and ubiquitin [10]. If these proteins show up inside the nucleus, it is a hallmark sign of NIID [9].
  • Consistency: In many cases, the results of a skin biopsy and genetic testing align closely, though false negatives and non-specific findings can occur, requiring expert interpretation [6].

Distinguishing NIID from “Look-Alikes”

Several other conditions can mimic the symptoms or imaging of NIID. Your doctor will work to rule these out:

  • FXTAS (Fragile X-Associated Tremor/Ataxia Syndrome): This condition can cause similar tremors and even show similar protein clumps on a biopsy. It is distinguished by testing a different gene (FMR1) [11].
  • CADASIL: This is a genetic condition that causes “mini-strokes” and white matter changes. It is distinguished by testing the NOTCH3 gene [12].
  • MELAS: A mitochondrial disorder that causes stroke-like episodes. Doctors use metabolic tests and mitochondrial DNA testing to tell it apart from NIID [13].

By combining these three pillars—the MRI “ribbon,” the NOTCH2NLC genetic expansion, and the presence of p62-positive inclusions in a skin biopsy—your care team can build a clear picture of your health [1][2].

Common questions in this guide

Can NIID be ruled out if the MRI ribbon sign is missing?
No. A bright ribbon-like signal at the border between the brain’s gray and white matter is a strong clue for NIID, but it may be absent early, disappear in very late disease, or change during stroke-like episodes. Doctors interpret the MRI alongside genetic and biopsy findings.
What does NOTCH2NLC testing look for in NIID?
The test looks for an expanded GGC repeat in the NOTCH2NLC gene, often more than 60 repeats, although laboratories may use different cutoffs. Repeat-primed PCR is commonly used, and long-read sequencing may help when the expansion is unusually large or difficult to read.
What if my NOTCH2NLC genetic test is negative?
A negative result does not always end the evaluation when symptoms and MRI findings still point toward NIID. A doctor may recommend a skin biopsy, review whether the test could detect the expansion, or investigate another condition.
How can a skin biopsy support an NIID diagnosis?
Pathologists examine cells from the skin, including cells in sweat glands, fat, or connective tissue, for round protein clumps inside the nucleus. Special stains for p62 and ubiquitin can make these inclusions visible, but a biopsy can be negative or nonspecific and needs expert interpretation.
Which conditions can mimic NIID, and how are they checked?
FXTAS can resemble NIID and is evaluated with testing of the FMR1 gene, while CADASIL is checked with NOTCH3 testing. MELAS may require metabolic and mitochondrial DNA tests because it can also cause stroke-like episodes.

Get notified when new evidence is published on Neuronal intranuclear inclusion disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Expanding the clinical spectrum of adult-onset neuronal intranuclear inclusion disease.

    Cao Y, Wu J, Yue Y, et al.

    Acta neurologica Belgica 2022; (122(3)):647-658 doi:10.1007/s13760-021-01622-4.

    PMID: 33625684
  2. 2

    A comprehensive study of clinicopathological and genetic features of neuronal intranuclear inclusion disease.

    Liu M, Gao Y, Yuan Y, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(10)):3545-3556 doi:10.1007/s10072-023-06845-2.

    PMID: 37184590
  3. 3

    Neuronal intranuclear inclusion disease in patients with adult-onset non-vascular leukoencephalopathy.

    Liu YH, Chou YT, Chang FP, et al.

    Brain : a journal of neurology 2022; (145(9)):3010-3021 doi:10.1093/brain/awac135.

    PMID: 35411397
  4. 4

    Longitudinal course of hyperintensity on diffusion weighted imaging in adult-onset neuronal intranuclear inclusion disease patients.

    Liu D, Chen K, Tan S, et al.

    Frontiers in neurology 2023; (14()):1178307 doi:10.3389/fneur.2023.1178307.

    PMID: 37404945
  5. 5

    Current advances in neuronal intranuclear inclusion disease.

    Bao L, Zuo D, Li Q, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(6)):1881-1889 doi:10.1007/s10072-023-06677-0.

    PMID: 36795299
  6. 6

    Case Report: Neuronal intranuclear inclusion disease mimicking recurrent stroke in the setting of intracranial stenosis.

    Zhao J, Shen G, Chi L

    Frontiers in medicine 2026; (13()):1838444 doi:10.3389/fmed.2026.1838444.

    PMID: 42245955
  7. 7

    Detection and characterization of rare variants in NOTCH2NLC causing false negative molecular diagnosis through long-read sequencing.

    Zheng X, Jin N, Liu P, et al.

    European journal of human genetics : EJHG 2025; (33(9)):1207-1211 doi:10.1038/s41431-025-01892-z.

    PMID: 40514451
  8. 8

    The clinical characteristics of neuronal intranuclear inclusion disease and its relation with inflammation.

    Yan Y, Cao L, Gu L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(9)):3189-3197 doi:10.1007/s10072-023-06822-9.

    PMID: 37099235
  9. 9

    The Value of NOTCH2NLC Gene Detection and Skin Biopsy in the Diagnosis of Neuronal Intranuclear Inclusion Disease.

    Pang J, Yang J, Yuan Y, et al.

    Frontiers in neurology 2021; (12()):624321 doi:10.3389/fneur.2021.624321.

    PMID: 34017298
  10. 10

    Neuronal intranuclear inclusion disease: two case report and literature review.

    Qin X, Chen H, Zhou C, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(1)):293-296 doi:10.1007/s10072-020-04613-0.

    PMID: 32839883
  11. 11

    FXTAS is difficult to differentiate from neuronal intranuclear inclusion disease through skin biopsy: a case report.

    Toko M, Ohshita T, Kurashige T, et al.

    BMC neurology 2021; (21(1)):396 doi:10.1186/s12883-021-02425-z.

    PMID: 34641814
  12. 12

    Clinical and imaging characteristics of NOTCH3-negative CADASIL-suspected patients with NOTCH2NLC GGC repeat expansions.

    Matsuura H, Fukunaga D, Mizuta I, et al.

    Journal of human genetics 2026; (71(8)):479-484 doi:10.1038/s10038-026-01470-1.

    PMID: 41882342
  13. 13

    Neuronal Intranuclear Inclusion Disease Presenting with Acute-Onset Dementia and Cortical Edema: A Case Report.

    Feng X, Li Y, Zhao Q, Xu S

    Frontiers in neurology 2024; (15()):1464991 doi:10.3389/fneur.2024.1464991.

    PMID: 39529621

This page is for informational purposes only and does not constitute medical advice. Your neurologist and other healthcare professionals should interpret your MRI, genetic, and biopsy results and discuss the next steps with you.